Research programme: HSP90 inhibitors - KeyNeurotek AGAlternative Names: SRN 005
Latest Information Update: 26 Feb 2008
At a glance
- Originator KeyNeurotek AG
- Developer KeyNeurotek Pharmaceuticals AG
- Class Small molecules
- Mechanism of Action Heat-shock protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Jul 2004 Preclinical trials in Cancer in Germany (unspecified route)